Ginkgo Bioworks DNA Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities.
The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ginkgo Bioworks's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ginkgo Bioworks's change in accrued liabilities?
- Ginkgo Bioworks (DNA) reported change in accrued liabilities of -$11.6M in Q1 2026.
- How has Ginkgo Bioworks's change in accrued liabilities changed year-over-year?
- Ginkgo Bioworks's change in accrued liabilities decreased by 230.8% year-over-year, from $8.87M to -$11.6M.
- What is the long-term trend for Ginkgo Bioworks's change in accrued liabilities?
- Over 3 years (2021 to 2024), Ginkgo Bioworks's change in accrued liabilities has grown at a -3.4% compound annual growth rate (CAGR), from $44.8M to -$40.44M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.